Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials

  • Author Footnotes
    d Yanxia Liu and Wanqiang Ma contributed equally to this article.
    Yanxia Liu
    Footnotes
    d Yanxia Liu and Wanqiang Ma contributed equally to this article.
    Affiliations
    The Second Cadres Ward, General Hospital of Shenyang Military Area Command, Shenyang City, Liaoning Province 110840, China
    Search for articles by this author
  • Author Footnotes
    d Yanxia Liu and Wanqiang Ma contributed equally to this article.
    Wanqiang Ma
    Footnotes
    d Yanxia Liu and Wanqiang Ma contributed equally to this article.
    Affiliations
    The 210th Hospital of PLA, Dalian City, Liaoning Province 116000, China
    Search for articles by this author
  • Po Zhang
    Affiliations
    Department of Congenital Heart Disease, Cardiovascular Research Institute of PLA, General Hospital of Shenyang Military Area Command, Shenyang City, Liaoning Province 110840, China
    Search for articles by this author
  • Shunchuan He
    Affiliations
    The Second Cadres Ward, General Hospital of Shenyang Military Area Command, Shenyang City, Liaoning Province 110840, China
    Search for articles by this author
  • Daifa Huang
    Correspondence
    Corresponding author. The Second Cadres Ward, General Hospital of Shenyang Military Area Command, No. 83 Wenhua Road, Shenhe District, Shenyang City, Liaoning Province 110840, China. Tel./fax: +86 2428851186.
    Affiliations
    The Second Cadres Ward, General Hospital of Shenyang Military Area Command, Shenyang City, Liaoning Province 110840, China
    Search for articles by this author
  • Author Footnotes
    d Yanxia Liu and Wanqiang Ma contributed equally to this article.
Published:April 02, 2014DOI:https://doi.org/10.1016/j.clnu.2014.03.009

      Summary

      Background & aims

      The results of human clinical trials that have investigated the effects of resveratrol on blood pressure are inconsistent. We aimed to quantitatively evaluate the effects of resveratrol on systolic blood pressure (SBP) and diastolic blood pressure (DBP).

      Methods

      We conducted a strategic literature search of PubMed, EMBASE, MEDLINE, and the Cochrane Library (updated to January, 2014) for randomized controlled trials that evaluate the effects of resveratrol on SBP and DBP. Study quality was assessed using the Jadad scale. Weighted mean differences were calculated for net changes in SBP and DBP using fixed-effects or random-effects models. We performed pre-specified subgroup, sensitivity and meta-regression analyses to evaluate potential the heterogeneity. Dose effects of resveratrol on SBP and DBP were estimated using meta-regression analyses.

      Results

      Six studies comprising a total of 247 subjects were included in our meta-analysis. The overall outcome of the meta-analysis indicates that resveratrol consumption can not significantly reduce SBP and DBP. Subgroup analyses indicated that higher-dose of resveratrol consumption (≥150 mg/d) significantly reduces SBP of −11.90 mmHg (95% CI: −20.99, −2.81 mmHg, P = 0.01), whereas lower dose of resveratrol did not show a significant lowering effect on SBP. The meta-regression analyses did not indicate dose effects of resveratrol on SBP or DBP.

      Conclusions

      The present meta-analysis indicates that resveratrol consumption significantly decreases the SBP level at the higher dose, while resveratrol has no significant effects on DBP levels. Additional high-quality studies are needed to further evaluate the causal conclusions.

      Keywords

      Abbreviations:

      BMI (body mass index), CVD (cardiovascular disease), DBP (diastolic blood pressure), GE (grape extract), GE-RES (grape extract containing resveratrol), RCTs (randomized controlled trials), SBP (systolic blood pressure), T2DM (type 2 diabetes mellitus)
      To read this article in full you will need to make a payment
      Subscribe to Clinical Nutrition
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Worlld Health Organization
        Cardiovascular disease: global atlas on cardiovascular disease prevention and control.
        WHO, Geneva, Switzerland2012
        • Smith Jr., S.C.
        • Collins A.
        • Ferrari R.
        • Holmes Jr., D.R.
        • Logstrup S.
        • McGhie D.V.
        • et al.
        Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke).
        J Am Coll Cardiol. 2012; 60: 2343-2348
        • Tome-Carneiro J.
        • Gonzalvez M.
        • Larrosa M.
        • Yanez-Gascon M.J.
        • Garcia-Almagro F.J.
        • Ruiz-Ros J.A.
        • et al.
        Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective.
        Ann N Y Acad Sci. 2013; 1290: 37-51
        • Das M.
        • Das D.K.
        Resveratrol and cardiovascular health.
        Mol Aspects Med. 2010; 31: 503-512
        • Wang H.
        • Yang Y.J.
        • Qian H.Y.
        • Zhang Q.
        • Xu H.
        • Li J.J.
        Resveratrol in cardiovascular disease: what is known from current research.
        Heart Fail Rev. 2012; 17: 437-448
        • Dohadwala M.M.
        • Vita J.A.
        Grapes and cardiovascular disease.
        J Nutr. 2009; 139: 1788S-1793S
        • Adab P.
        • Cheng K.K.
        • Jiang C.Q.
        • Zhang W.S.
        • Lam T.H.
        Age-specific relevance of usual blood pressure to vascular mortality.
        Lancet. 2003; 361 (author reply 1391–2): 1391
        • Collins R.
        • MacMahon S.
        Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease.
        Br Med Bull. 1994; 50: 272-298
        • Lewington S.
        • Clarke R.
        • Qizilbash N.
        • Peto R.
        • Collins R.
        Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
        Lancet. 2002; 360: 1903-1913
        • Barona J.
        • Aristizabal J.C.
        • Blesso C.N.
        • Volek J.S.
        • Fernandez M.L.
        Grape polyphenols reduce blood pressure and increase flow-mediated vasodilation in men with metabolic syndrome.
        J Nutr. 2012; 142: 1626-1632
        • Feringa H.H.
        • Laskey D.A.
        • Dickson J.E.
        • Coleman C.I.
        The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials.
        J Am Diet Assoc. 2011; 111: 1173-1181
        • van Mierlo L.A.
        • Zock P.L.
        • van der Knaap H.C.
        • Draijer R.
        Grape polyphenols do not affect vascular function in healthy men.
        J Nutr. 2010; 140: 1769-1773
        • Sivaprakasapillai B.
        • Edirisinghe I.
        • Randolph J.
        • Steinberg F.
        • Kappagoda T.
        Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome.
        Metabolism. 2009; 58: 1743-1746
        • Sano A.
        • Uchida R.
        • Saito M.
        • Shioya N.
        • Komori Y.
        • Tho Y.
        • et al.
        Beneficial effects of grape seed extract on malondialdehyde-modified LDL.
        J Nutr Sci Vitaminol (Tokyo). 2007; 53: 174-182
        • Ward N.C.
        • Hodgson J.M.
        • Croft K.D.
        • Burke V.
        • Beilin L.J.
        • Puddey I.B.
        The combination of vitamin C and grape-seed polyphenols increases blood pressure: a randomized, double-blind, placebo-controlled trial.
        J Hypertens. 2005; 23: 427-434
        • Clifton P.M.
        Effect of grape seed extract and quercetin on cardiovascular and endothelial parameters in high-risk subjects.
        J Biomed Biotechnol. 2004; 2004: 272-278
        • Zou J.G.
        • Wang Z.R.
        • Huang Y.Z.
        • Cao K.J.
        • Wu J.M.
        Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits.
        Int J Mol Med. 2003; 11: 317-320
        • Lekli I.
        • Szabo G.
        • Juhasz B.
        • Das S.
        • Das M.
        • Varga E.
        • et al.
        Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin.
        Am J Physiol Heart Circ Physiol. 2008; 294: H859-H866
        • Liu Z.
        • Song Y.
        • Zhang X.
        • Liu Z.
        • Zhang W.
        • Mao W.
        • et al.
        Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model.
        Clin Exp Pharmacol Physiol. 2005; 32: 1049-1054
        • Moher D.
        • Pham B.
        • Jones A.
        • Cook D.J.
        • Jadad A.R.
        • Moher M.
        • et al.
        Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses.
        Lancet. 1998; 352: 609-613
        • Higgins J.P.
        • Thompson S.G.
        • Deeks J.J.
        • Altman D.G.
        Measuring inconsistency in meta-analyses.
        BMJ. 2003; 327: 557-560
        • Follmann D.
        • Elliott P.
        • Suh I.
        • Cutler J.
        Variance imputation for overviews of clinical trials with continuous response.
        J Clin Epidemiol. 1992; 45: 769-773
        • Movahed A.
        • Nabipour I.
        • Lieben L.X.
        • Thandapilly S.J.
        • Yu L.
        • Kalantarhormozi M.
        • et al.
        Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients.
        Evid Based Complement Altern Med. 2013; 2013: 851267
        • Bhatt J.K.
        • Thomas S.
        • Nanjan M.J.
        Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus.
        Nutr Res. 2012; 32: 537-541
        • Yoshino J.
        • Conte C.
        • Fontana L.
        • Mittendorfer B.
        • Imai S.
        • Schechtman K.B.
        • et al.
        Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance.
        Cell Metab. 2012; 16: 658-664
        • Tome-Carneiro J.
        • Gonzalvez M.
        • Larrosa M.
        • Yanez-Gascon M.J.
        • Garcia-Almagro F.J.
        • Ruiz-Ros J.A.
        • et al.
        One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease.
        Am J Cardiol. 2012; 110: 356-363
        • Fujitaka K.
        • Otani H.
        • Jo F.
        • Jo H.
        • Nomura E.
        • Iwasaki M.
        • et al.
        Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment.
        Nutr Res. 2011; 31: 842-847
        • Timmers S.
        • Konings E.
        • Bilet L.
        • Houtkooper R.H.
        • van de Weijer T.
        • Goossens G.H.
        • et al.
        Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.
        Cell Metab. 2011; 14: 612-622
        • Ishii M.
        The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension.
        Nihon Rinsho. 2000; 58: 267-275
        • Boocock D.J.
        • Patel K.R.
        • Faust G.E.
        • Normolle D.P.
        • Marczylo T.H.
        • Crowell J.A.
        • et al.
        Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography.
        J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 848: 182-187
        • Walle T.
        • Hsieh F.
        • DeLegge M.H.
        • Oatis Jr., J.E.
        • Walle U.K.
        High absorption but very low bioavailability of oral resveratrol in humans.
        Drug Metab Dispos. 2004; 32: 1377-1382
        • Rivera L.
        • Moron R.
        • Zarzuelo A.
        • Galisteo M.
        Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats.
        Biochem Pharmacol. 2009; 77: 1053-1063
        • Inanaga K.
        • Ichiki T.
        • Matsuura H.
        • Miyazaki R.
        • Hashimoto T.
        • Takeda K.
        • et al.
        Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis.
        Hypertens Res. 2009; 32: 466-471
        • Chan V.
        • Fenning A.
        • Iyer A.
        • Hoey A.
        • Brown L.
        Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats.
        Curr Pharm Biotechnol. 2011; 12: 429-436
        • Toklu H.Z.
        • Sehirli O.
        • Ersahin M.
        • Suleymanoglu S.
        • Yiginer O.
        • Emekli-Alturfan E.
        • et al.
        Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats.
        J Pharm Pharmacol. 2010; 62: 1784-1793
        • Miatello R.
        • Vazquez M.
        • Renna N.
        • Cruzado M.
        • Zumino A.P.
        • Risler N.
        Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats.
        Am J Hypertens. 2005; 18: 864-870
        • Robich M.P.
        • Chu L.M.
        • Chaudray M.
        • Nezafat R.
        • Han Y.
        • Clements R.T.
        • et al.
        Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome.
        Surgery. 2010; 148: 453-462
        • Csiszar A.
        • Labinskyy N.
        • Olson S.
        • Pinto J.T.
        • Gupte S.
        • Wu J.M.
        • et al.
        Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats.
        Hypertension. 2009; 54: 668-675
        • Rush J.W.
        • Quadrilatero J.
        • Levy A.S.
        • Ford R.J.
        Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats.
        Exp Biol Med (Maywood). 2007; 232: 814-822
        • Thandapilly S.J.
        • Wojciechowski P.
        • Behbahani J.
        • Louis X.L.
        • Yu L.
        • Juric D.
        • et al.
        Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure.
        Am J Hypertens. 2010; 23: 192-196
        • Dolinsky V.W.
        • Chan A.Y.
        • Robillard F.I.
        • Light P.E.
        • Des Rosiers C.
        • Dyck J.R.
        Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1.
        Circulation. 2009; 119: 1643-1652
        • Mizutani K.
        • Ikeda K.
        • Kawai Y.
        • Yamori Y.
        Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats.
        Clin Exp Pharmacol Physiol. 2001; 28: 55-59
        • Vidt D.G.
        • Borazanian R.A.
        Treat high blood pressure sooner: tougher, simpler JNC 7 guidelines.
        Cleve Clin J Med. 2003; 70: 721-728